MerseyBIO is an incubator for young biotechnology businesses. Backed by the University of Liverpool and National Health Service, the company provides office and laboratory space, as well as business, investment, and technical support services to biotechnology entrepreneurs. MerseyBIO, which can incubate up to 15 biotechnology businesses, also networks its member biotechnology companies with other biotechnology firms and resources around the world. Provexis plc became the first flotation of a MerseyBIO-based company.

Genta plays rough with cancer. The firm develops drugs, including DNA/RNA medicines and more traditional small molecule drugs, for cancer and other diseases. Lead candidate Genasense blocks production of a protein that can cause resistance to cancer treatments. The company is hoping for marketing approval of Genasense to be used in conjunction with chemotherapy by patients with lymphocytic leukemia and malignant melanoma. Genasense is also in clinical trials for treatment of other diseases, such as prostate and colon cancer. Its small molecule program yielded Ganite, an FDA-approved treatment for hypercalcemia (a potentially fatal side effect of cancer); but the company does not actively market the drug.

Roxane Laboratories, a US-based subsidiary of Germany's Boehringer Ingelheim, oversees the development, manufacturing, and marketing of its parent company's multisource (generic) drugmaking business in the US. It sells about 75 medications in 250 package sizes, focusing on oral liquids, sustained-release and controlled-release tablets, cancer drugs, and nasal sprays. It also distributes narcotics, such as meperidine (generic Demerol) and methadone. Products developed and marketed by Roxane are manufactured by its sister company, Boehringer Inghelheim Roxane, also located in Columbus, Ohio.

Zeltia SA is a Spain-based holding company primarily engaged, through its subsidiaries, in the chemical and pharmaceutical sectors. Its main subsidiaries are: PharmaMar SA, biopharmaceutical company committed to advancing the treatment of cancer; Noscira SA, engaged in the research and development of innovative drugs for diseases of the nervous system; Genomica SAU, specializes in molecular diagnosis; Sylentis SAU, focused on the discovering and developing new therapeutic approaches based on gene silencing techniques; Zelnova SA, which produces and markets cleaning products for household and cetring sectors; and Xylazel SA, producer of paints, varnishes, wood and metal protectors for the industrial sector.

Mitsubishi Tanabe Pharma makes proprietary prescription pharmaceuticals in a number of therapeutic areas, including cardiovascular disease, diabetes, neuroscience, immunology, and oncology. In its home market, it sells products such as anticoagulant Anplag, anti-allergy medicine Talion, liver drug Urso, and neuroprotective agent Radicut. Its Benesis unit makes therapeutic plasma proteins such as albumin. The company markets and sells its products through in-house sales agents and distributors. Formerly Mitsubishi Pharma, the company merged with fellow Japanese drugmaker Tanabe Seiyaku and subsequently changed its name; Mitsubishi Chemical Holdings owns a majority stake in the new entity.

For biotechnology and pharmaceutical companies whose next big breakthrough is stuck in the test tube, Oxford Therapeutics Consulting could have the answer. The product development consulting firm offers strategic planning and product management for biotechs and pharmas that are short on staff and experience in bringing a new product through the lengthy development pipeline. Oxford Therapeutics' team of consultants work primarily with smaller companies on products such as anticancer agents, antibacterial and antiviral compounds, and therapeutic vaccines.

AVI BioPharma, Inc. was founded in 1980 and is based in Corvallis, Oregon. AVI BioPharma, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutic products based on antisense and cancer immunotherapy technology. The company's products under various development stages comprise AVI-4658, a Phase I human clinical trial product to restore, prevent, or slow deterioration of muscle function; AVI-5038, a preclinical stage product to skip exon 50 and restore a range of associated mutations; AVI-5126, a Phase II clinical trial product for the treatment of cardiovascular restenosis; and AVI-6002 and AVI6003, which are in Phase I clinical trials to treat diseases caused by Dengue, Ebola, Marburg, and Junín viruses. It has strategic alliances with Chiron Corporation; Cook Group Incorporated; Ercole Biotech, Inc.; Eleos Inc.; Charley's Fund, Inc.; and the United States Department of Defense.

AutoGenomics was founded in 1999 as Neuron Technologies and applied to go public in 2008. AutoGenomics, Inc. company developed a genetic testing system called INFINITI that scans DNA samples for genetic disorders, infectious diseases, cancer, and pharmacogenetics (a patient's genetic likeliness to have an adverse reaction to a drug). AutoGenomics found about 25 uses for the INFINITI, but only four have been approved by the FDA for diagnostic use -- testing for sensitivity to the popular blood thinner warfarin, screening for the risk of developing cystic fibrosis or cervical cancer (for women with HPV), and testing for a gene that blocks common drugs from working.

Novartis AG company was founded in 1895 and is headquartered in Basel, Switzerland. Novartis AG, through its subsidiaries, engages in the research, development, manufacture, and marketing of healthcare products worldwide. Its Pharmaceuticals division engages in the research, development, manufacture, distribution, and sale of pharmaceuticals in various therapeutic areas, including cardiovascular and metabolism; oncology; neuroscience and ophthalmics; respiratory; and immunology and infectious diseases. Novartis company's Vaccines and Diagnostics division offers preventive vaccines and diagnostic tools. This division provides influenza, meningococcal, pediatric, and traveler vaccines; and blood testing and molecular diagnostics to prevent the spread of infectious diseases. Its Sandoz division offers prescription medicines, as well as pharmaceutical and biotechnological active substances. This division provides active ingredients and finished dosage forms of pharmaceuticals; anti-infectives; protein or biotechnology-based products; and cytotoxic products, as well as offers biotech manufacturing services to other companies on a contract basis. Novartis company's Consumer Health division consists of three business units: over-the-counter medicines (OTC), Animal Health, and CIBA Vision. OTC offers readily available consumer medicines. Animal Health provides veterinary products for farm and companion animals. CIBA Vision manufactures contact lenses and lens care products. Novartis AG has a strategic alliance with Intercell AG to develop vaccines; and a strategic partnership with Lonza, a Swiss pharmaceuticals manufacturing company.

Penn Pharmaceutical Services wants to help you by helping others, specifically pharmaceutical companies. Penn offers a variety of products and services: clinical trial supplies; formulation and analytical development; chemistry, manufacturing, and controls (CMC) consultancy; qualified person (QP) audits; and contract manufacturing services. It also offers logistical management services, such as exporting and reporting. In 2007 Penn, which serves many US clients, opened an American arm, Penn Pharmaceutical Services US, in Philadelphia.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.